Literature DB >> 1838679

Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes.

M S Freedman1, T C Ruijs, L K Selin, J P Antel.   

Abstract

T cells are postulated to contribute to the injury of the oligodendrocyte-myelin complex underlying the demyelinating disease multiple sclerosis (MS). The apparent lack of class I or II major histocompatibility complex (MHC) expression in situ on human oligodendrocytes and the consistent failure to identify a universal myelin antigen in MS suggest that the immune damage might be mediated by effector T cells that are capable of reacting in an antigen-nonspecific and possibly MHC-unrestricted manner, such as T cells expressing the gamma-delta T-cell receptor. Since gamma-delta T cells are reported to be present in MS plaques and an increased number are found in the cerebrospinal fluid of patients with MS, we directly examined whether gamma-delta T cells are capable of inducing injury to human oligodendrocytes. We found, using a 6-hour 51Cr release assay, that oligodendrocytes cultured from surgically resected human brain specimens were effectively lysed in a dose-dependent manner by human gamma-delta T cells (28 +/- 5% mean specific lysis, n = 6, at an effector-target ratio of 20:1). Although heat shock protein HSP72, a putative gamma-delta T-cell recognition molecule, could be induced in vitro in our oligodendrocytes, an antibody to HSP72 did not inhibit gamma-delta T cell-mediated lysis of oligodendrocytes. These results suggest that gamma-delta T cells gaining entry into the central nervous system may be deleterious to oligodendrocytes and thus may contribute to the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838679     DOI: 10.1002/ana.410300608

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  gamma delta T cells in autoimmunity.

Authors:  Z Yin; J Craft
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Heat shock protein 70: roles in multiple sclerosis.

Authors:  María José Mansilla; Xavier Montalban; Carmen Espejo
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 3.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

4.  γδ T cell subsets play opposing roles in regulating experimental autoimmune encephalomyelitis.

Authors:  Sarah E Blink; Matthew W Caldis; Gwendolyn E Goings; Christopher T Harp; Bernard Malissen; Immo Prinz; Dan Xu; Stephen D Miller
Journal:  Cell Immunol       Date:  2014-05-10       Impact factor: 4.868

Review 5.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions?

Authors:  H Lassmann; K Vass
Journal:  Springer Semin Immunopathol       Date:  1995

Review 7.  Lame ducks or fierce creatures? The role of oligodendrocytes in multiple sclerosis.

Authors:  T Zeis; N Schaeren-Wiemers
Journal:  J Mol Neurosci       Date:  2008-02-16       Impact factor: 3.444

Review 8.  gammadelta T cells: the overlooked T-cell subset in demyelinating disease.

Authors:  Jillian E Wohler; Sherry S Smith; Scott R Barnum
Journal:  J Neurosci Res       Date:  2010-01       Impact factor: 4.164

Review 9.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

10.  Gamma delta T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions.

Authors:  L Battistini; M Salvetti; G Ristori; M Falcone; C S Raine; C F Brosnan
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.